Spectral AI Secures $31.7M Funding from BARDA
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MDAI?
Spectral AI announced that it has received $31.7M in funding from the Biomedical Advanced Research and Development Authority, or BARDA, to accelerate and support additional feature aspects for the company's DeepView System, its AI-driven burn wound imaging technology. As part of the ongoing partnership, Spectral AI has committed to provide an additional $9.7M to the total overall development costs associated with these feature advancements. This immediate, non-dilutive funding is being advanced in addition to the $54.9M of funding committed to date as part of the company's current contract with BARDA valued up to $150M, as the company awaits a determination on market authorization from the FDA for the DeepView System.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MDAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MDAI
Wall Street analysts forecast MDAI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.720
Low
3.00
Averages
4.50
High
6.00
Current: 1.720
Low
3.00
Averages
4.50
High
6.00
About MDAI
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Spectral AI Q4 Earnings Exceed Expectations
- Earnings Beat: Spectral AI reported a Q4 GAAP EPS of $0.02, surpassing expectations by $0.15, indicating significant improvement in profitability and boosting investor confidence.
- R&D Revenue Decline: The company’s R&D revenue of $3.8 million, down 50% year-over-year, still exceeded expectations by $0.88 million, showcasing effective management of R&D expenditures that may lay the groundwork for future product development.
- Cash Flow Improvement: As of December 31, 2025, cash reserves increased to $15.4 million from $5.2 million in 2024, reflecting significant progress in financial management and operational efficiency, which will support future growth initiatives.
- Future Revenue Guidance: The company forecasts approximately $18.5 million in revenue for the year ending December 31, 2026, primarily driven by ongoing development of the DeepView System through the BARDA PBS Contract, indicating a strong commitment to strategic projects and an optimistic market outlook.
See More
SPECTRAL AI INC REPORTS $3.8 MILLION IN REVENUE FOR Q4 2025
Company Overview: Spectral AI Inc. is projected to generate a revenue of $3.8 million in the fourth quarter of 2025.
Financial Forecast: The revenue estimate indicates potential growth and market presence for Spectral AI in the upcoming years.
See More
Spectral AI Secures $31.7 Million Funding for DeepView System Development
- Funding Acquisition: Spectral AI has secured $31.7 million from the Biomedical Advanced Research and Development Authority (BARDA) to expedite the development of its DeepView System, with an additional $9.7 million from the company, bringing total funding to nearly $55 million, reflecting strong confidence in the technology.
- Technological Innovation: The DeepView System employs proprietary multispectral imaging and AI to assist physicians in quickly assessing whether burn wounds require surgical intervention, which is critical in mass casualty incidents, enabling rapid triage that can save lives and optimize the use of limited medical resources.
- FDA Clearance Efforts: CEO Vincent Capone emphasized that the partnership with BARDA not only bolsters efforts to secure FDA clearance for commercial distribution but also supports the development of new features such as total body surface area mapping, enhancing the technology's application potential.
- Market Performance: MDAI's stock has traded between $1.04 and $3.21 over the past year, closing at $1.20 on Wednesday with a 6.25% decline, yet it rose to $1.63 in overnight trading, reflecting a 35.83% increase, indicating a positive market reaction to the funding news.
See More
Spectral AI to Report Q4 and Full Year 2025 Financial Results on March 24, 2026
- Earnings Report Schedule: Spectral AI will release its financial results for Q4 and the full year 2025 on March 24, 2026, after market close, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: The company will host a conference call at 5:00 PM Eastern Time on the same day, allowing investors to dial in at 833-890-6620 for U.S. or 412-564-3789 for international participation, enhancing investor engagement.
- DeepView System Overview: The DeepView system being developed by Spectral AI aims to provide clinicians with an objective assessment of burn wound healing potential through algorithm-driven results, which is expected to significantly improve wound care management efficiency and patient outcomes.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech companies for 2025, highlighting its innovative capabilities and market impact in the medical diagnostics field.
See More
Spectral AI Appoints New CEO Vincent Capone
- Executive Appointment: Spectral AI has appointed Vincent Capone as Chief Executive Officer, effective February 9, 2026, with Capone having served as Chief Financial Officer since February 2024, bringing extensive financial management experience to the role.
- Legal Expertise: Prior to his CFO role, Capone was the General Counsel since March 2022, showcasing his dual expertise in legal and financial matters, which will aid the company in compliance and strategic financial decisions.
- Board Membership: Capone has been a member of the Office of the Chairman since October 2024, participating in high-level decision-making, which enhances his influence in corporate governance and is expected to drive future growth strategies for the company.
- Market Reaction: Following the announcement, Spectral AI's stock price rose 1.93% in premarket trading to $1.58, indicating positive market expectations regarding the new CEO's leadership.
See More
Spectral AI Appoints New CEO to Drive Commercialization
- New CEO Appointment: Spectral AI appointed Vincent S. Capone as CEO effective February 9, 2026, transitioning from his role as CFO and General Counsel, which is expected to accelerate the commercialization of the non-invasive AI-driven burn wound assessment device, DeepView®System.
- Leadership Background: Capone brings a diverse background in law, accounting, finance, and operations management, with Chairman Dr. J. Michael DiMaio noting that his leadership skills and vision for the company's future will help ensure the evolution of its strategic direction.
- Key Milestone: The submission of the DeepView System to the FDA in June 2025 marks a significant step forward for Spectral AI, aiming to provide innovative technology that enhances burn wound care in the U.S. and globally.
- Industry Recognition: Spectral AI was named one of TIME's Top HealthTech companies for 2025, highlighting its potential and impact in the medical diagnostics field.
See More
Spectral AI Q4 Earnings Exceed Expectations
- Earnings Beat: Spectral AI reported a Q4 GAAP EPS of $0.02, surpassing expectations by $0.15, indicating significant improvement in profitability and boosting investor confidence.
- R&D Revenue Decline: The company’s R&D revenue of $3.8 million, down 50% year-over-year, still exceeded expectations by $0.88 million, showcasing effective management of R&D expenditures that may lay the groundwork for future product development.
- Cash Flow Improvement: As of December 31, 2025, cash reserves increased to $15.4 million from $5.2 million in 2024, reflecting significant progress in financial management and operational efficiency, which will support future growth initiatives.
- Future Revenue Guidance: The company forecasts approximately $18.5 million in revenue for the year ending December 31, 2026, primarily driven by ongoing development of the DeepView System through the BARDA PBS Contract, indicating a strong commitment to strategic projects and an optimistic market outlook.
See More
SPECTRAL AI INC REPORTS $3.8 MILLION IN REVENUE FOR Q4 2025
Company Overview: Spectral AI Inc. is projected to generate a revenue of $3.8 million in the fourth quarter of 2025.
Financial Forecast: The revenue estimate indicates potential growth and market presence for Spectral AI in the upcoming years.
See More
Spectral AI Secures $31.7 Million Funding for DeepView System Development
- Funding Acquisition: Spectral AI has secured $31.7 million from the Biomedical Advanced Research and Development Authority (BARDA) to expedite the development of its DeepView System, with an additional $9.7 million from the company, bringing total funding to nearly $55 million, reflecting strong confidence in the technology.
- Technological Innovation: The DeepView System employs proprietary multispectral imaging and AI to assist physicians in quickly assessing whether burn wounds require surgical intervention, which is critical in mass casualty incidents, enabling rapid triage that can save lives and optimize the use of limited medical resources.
- FDA Clearance Efforts: CEO Vincent Capone emphasized that the partnership with BARDA not only bolsters efforts to secure FDA clearance for commercial distribution but also supports the development of new features such as total body surface area mapping, enhancing the technology's application potential.
- Market Performance: MDAI's stock has traded between $1.04 and $3.21 over the past year, closing at $1.20 on Wednesday with a 6.25% decline, yet it rose to $1.63 in overnight trading, reflecting a 35.83% increase, indicating a positive market reaction to the funding news.
See More
Spectral AI to Report Q4 and Full Year 2025 Financial Results on March 24, 2026
- Earnings Report Schedule: Spectral AI will release its financial results for Q4 and the full year 2025 on March 24, 2026, after market close, which is expected to provide investors with critical financial data and future outlook.
- Conference Call Details: The company will host a conference call at 5:00 PM Eastern Time on the same day, allowing investors to dial in at 833-890-6620 for U.S. or 412-564-3789 for international participation, enhancing investor engagement.
- DeepView System Overview: The DeepView system being developed by Spectral AI aims to provide clinicians with an objective assessment of burn wound healing potential through algorithm-driven results, which is expected to significantly improve wound care management efficiency and patient outcomes.
- Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech companies for 2025, highlighting its innovative capabilities and market impact in the medical diagnostics field.
See More
Spectral AI Appoints New CEO Vincent Capone
- Executive Appointment: Spectral AI has appointed Vincent Capone as Chief Executive Officer, effective February 9, 2026, with Capone having served as Chief Financial Officer since February 2024, bringing extensive financial management experience to the role.
- Legal Expertise: Prior to his CFO role, Capone was the General Counsel since March 2022, showcasing his dual expertise in legal and financial matters, which will aid the company in compliance and strategic financial decisions.
- Board Membership: Capone has been a member of the Office of the Chairman since October 2024, participating in high-level decision-making, which enhances his influence in corporate governance and is expected to drive future growth strategies for the company.
- Market Reaction: Following the announcement, Spectral AI's stock price rose 1.93% in premarket trading to $1.58, indicating positive market expectations regarding the new CEO's leadership.
See More
Spectral AI Appoints New CEO to Drive Commercialization
- New CEO Appointment: Spectral AI appointed Vincent S. Capone as CEO effective February 9, 2026, transitioning from his role as CFO and General Counsel, which is expected to accelerate the commercialization of the non-invasive AI-driven burn wound assessment device, DeepView®System.
- Leadership Background: Capone brings a diverse background in law, accounting, finance, and operations management, with Chairman Dr. J. Michael DiMaio noting that his leadership skills and vision for the company's future will help ensure the evolution of its strategic direction.
- Key Milestone: The submission of the DeepView System to the FDA in June 2025 marks a significant step forward for Spectral AI, aiming to provide innovative technology that enhances burn wound care in the U.S. and globally.
- Industry Recognition: Spectral AI was named one of TIME's Top HealthTech companies for 2025, highlighting its potential and impact in the medical diagnostics field.
See More
